FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular, to vesicles originating from bacteria from the genus Sphingomonas, and to an application thereof.
EFFECT: vesicles originating from bacteria from the genus Sphingomonas can be successfully used to develop a method for diagnosing liver cirrhosis, liver cancer, myocardial infarction, renal failure, diabetes, brain tumours, moderate cognitive impairment, dementia, depression, autism, and atopic dermatitis, a composition for preventing, suppressing or treating the above diseases, and producing a carrier for delivering a medicinal substance to the brain.
10 cl, 17 dwg, 1 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STEM CELL PRODUCED FROM HUMAN MONOCYTE AND USED FOR THERAPEUTIC APPLICATION AND METHOD FOR INDUCING IT | 2009 |
|
RU2573906C2 |
| ANTI-IL-17 ANTIBODIES, METHODS OF THEIR PRODUCTION AND APPLICATION | 2014 |
|
RU2577228C2 |
| COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL OR MENTAL DISORDERS, CONTAINING EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS PARACASEI | 2021 |
|
RU2819806C1 |
| 4-FLUORO-N-INDANE-2-YLBENZAMIDE AND ITS USING AS PHARMACEUTICAL AGENT | 2002 |
|
RU2308946C2 |
| METHOD OF TREATING CHRONIC DERMATOSES | 2018 |
|
RU2709534C1 |
| COMPOUND WS727713 | 2005 |
|
RU2407785C2 |
| LEUCINE, ACETYLLECINE AND RELATED ANALOGUES FOR TREATMENT OF DISEASE | 2020 |
|
RU2815373C2 |
| INHIBITORS OF NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (HSEP) FOR REDUCTION IN HARMFUL EFFECTS OF PERFUSION ORGAN DEFICIENCY | 2019 |
|
RU2782919C2 |
| CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITIONS | 2010 |
|
RU2755902C2 |
| CONCENTRATED THERAPEUTIC PHOSPHOLIPIDE COMPOSITIONS | 2010 |
|
RU2642653C2 |
